InCube Ventures

InCube Ventures

InCube Ventures was established in 2011 by Mir Imran, a prolific medical device inventor and entrepreneur who previously founded InCube Labs in 1995. The venture firm formalizes an investment strategy that emerged organically from the lab's model: spinning out companies built on technologies developed within InCube's own R&D infrastructure. Imran, who holds more than 400 issued patents, structured the venture arm to capture equity in the companies his lab incubates, creating a tight loop between invention, proof-of-concept, and venture funding. The firm concentrates on health technology, with a portfolio spanning medical devices, digital therapeutics, and enterprise software for clinical settings. InCube Ventures participates primarily in seed and early-stage rounds, often as the first institutional capital into companies that originated inside InCube Labs. Known portfolio companies include Rani Therapeutics, which developed an oral biologics delivery platform and went public via SPAC in 2021 (per public record, 2021), and Cadence, a wireless vital-sign monitoring company acquired by Medtronic. The firm also invested in Corhythm, a cardiac rhythm management company, and InCube's portfolio extends across the United States and select international markets where the lab's technologies are commercialized. InCube Ventures operates with a lean team centered around Imran's technical and operational leadership. The broader InCube ecosystem includes InCube Labs locations in San Jose and Hyderabad, India, which serve as the core R&D engine. The lab's model generates deal flow that is proprietary by design — companies are built internally rather than sourced through competitive auctions or pitch decks. In 2013, InCube Labs raised a $33 million funding round backed by a group of strategic and institutional investors to accelerate company creation (per SEC filings, 2013). This capital structure gives the lab a balance-sheet runway independent of the venture fund's limited partner commitments, allowing company formation decisions to be driven by technical milestones rather than fundraising cycles. The structural differentiator is the complete integration of venture capital with a controlled research environment. InCube Ventures does not merely select promising startups; it invests in entities whose IP, prototypes, and early management teams were assembled within its parent incubator. This collapses the distance between scientific founder and venture investor and gives the firm a specific technical underwriting advantage distinct from generalist life sciences funds.